



치료목적사용면책 국제표준

INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS



2009 1



한국도핑방지위원회

UNOFFICIAL TRANSLATION

THE OFFICIAL TEXTS OF THE INTERNATIONAL STANDARD FOR THERAPEUTIC USE EXEMPTIONS ARE THE ENGLISH AND FRENCH VERSIONS MAINTAINED BY THE WORLD ANTI-DOPING AGENCY AND PUBLISHED ON ITS WEBSITE. THE ENGLISH VERSION SHALL PREVAIL IN THE EVENT OF ANY CONFLICT OF INTERPRETATION.

비공식 번역

치료목적 사용면책 국제표준의 공식 원본은 영어본과 불어본으로 세계반도핑기구가 유지·관리하며, 세계반도핑기구 웹사이트에 공표된다. 해석에 있어 서로 상충되는 경우, 영어본이 우선한다.

The World Anti-Doping Agency (WADA) wishes to acknowledge and thank the Korean Anti-Doping Agency (KADA) for their valuable contribution in the development of the Korean version of the International Standard for Therapeutic Use Exemptions. This enables the World Anti-Doping Code to be shared across countries globally so that WADA, the public authorities and the sports movement can work together towards the goal of eradicating doping in sport.

(WADA)

(KADA)

(WADA),

가

International Standard for Therapeutic Use Exemptions

The International Standard for Therapeutic Use Exemptions was first adopted in 2004 and became effective in 2005. The enclosed represents version 3.0 that incorporates revisions to the International Standard for Therapeutic Use Exemptions that were approved by the World Anti-Doping Agency Executive Committee on 10 May and 20 September 2008. The revised International Standard for Therapeutic Use Exemptions is effective as of 1 January 2009.

Published on 1 October 2008 by:

World Anti-Doping Agency
Stock Exchange Tower
800 Place Victoria (Suite 1700)
PO Box 120
Montreal, Quebec,
Canada H4Z 1B7

URL: www.wada-ama.org

Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: info@wada-ama.org

2004 2005
3.0 2008 5 10 2008 9 20
2009 1 1
2008 10 1 :

Stock Exchange Tower
800 Place Victoria (Suite 1700)
PO Box 120
Montreal, Quebec,
Canada H4Z 1B7

: www.wada-ama.org

: +1 514 904 9232
: +1 514 904 8650
E-mail: info@wada-ama.org

PREAMBLE

The World Anti-Doping Code *International Standard* for Therapeutic Use Exemptions (TUE) is a level 2 mandatory *International Standard* developed as part of the World Anti-Doping Program.

The basis for the development of the *International Standard* for TUE has been a review of various procedures and protocols of International Federations, the IOC, National Anti-Doping Organizations and relevant sections in the revised International Standard for Doping Control (ISDC). A WADA expert reference group reviewed, discussed and prepared the document following wide consultation and consideration of submissions.

The official text of the *International Standard* for Therapeutic Use Exemption shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

The *International Standard* for TUE (version 3.0) will come into effect on 1

Therapeutic Use Exemptions) (International Standard for
2

가 (International Standard for
Doping Control : ISDC)

가

가

(3.0) 2009 1 1

TABLE OF CONTENTS

PART ONE: INTRODUCTION, CODE PROVISIONS AND DEFINITIONS.....	5
1.0 Introduction and Scope.....	5
2.0 <i>Code</i> Provisions	6
3.0 Terms and Definitions.....	8
3.1 Defined Terms from the <i>Code</i>	8
3.2 Defined Terms from the <i>International Standard</i> for TUEs.....	12
PART TWO: STANDARDS FOR GRANTING THERAPEUTIC USE EXEMPTIONS	13
4.0 Criteria for Granting a <i>Therapeutic Use</i> Exemption.....	13
5.0 Confidentiality of Information	14
6.0 <i>Therapeutic Use</i> Exemption Committees (TUECs).....	15
7.0 <i>Therapeutic Use</i> Exemption (TUE) Application Process.....	15
8.0 Declaration of <i>Use</i> Process.....	18
9.0 Clearinghouse.....	18
10.0 Transitional provision.....	18
ANNEX 1:.....	20
Minimal requirements for the medical file to be used for the TUE process in the case of asthma and its clinical variants.....	20
ANNEX 2:.....	21
Therapeutic use exemption application form.....	21
ANNEX 3:.....	23
Therapeutic use exemption Committee Decision.....	23

차 례

1 : ,	5
1.0	5
2.0	6
3.0	8
3.1	8
3.2	12
2 :	13
4.0	13
5.0	14
6.0 (TUECs)	15
7.0	15
8.0	18
9.0	18
10.0	18
1.....	20
.....	20
2.....	21
.....	21
3.....	23
.....	23

2.2), *Possession of Prohibited Substances and Prohibited Methods* (Article 2.6) or Administration or *Attempted Administration* of a *Prohibited Substance* or *Prohibited Method* (Article 2.8) consistent with the provisions of an applicable therapeutic use exemption issued pursuant to the *International Standard for Therapeutic Use Exemptions* shall not be considered an anti-doping rule violation.

Code Article 13.4 Appeals from Decisions Granting or Denying a Therapeutic Use Exemption

Decisions by *WADA* reversing the grant or denial of a therapeutic use exemption may be appealed exclusively to *CAS* by the *Athlete* or the *Anti-Doping Organization* whose decision was reversed. Decisions by *Anti-Doping Organizations* other than *WADA* denying therapeutic use exemptions, which are not reversed by *WADA*, may be appealed by *International-Level Athletes* to *CAS* and by other *Athletes* to the national-level reviewing body described in Article 13.2.2. If the national-level reviewing body reverses the decision to deny a therapeutic use exemption, that decision may be appealed to *CAS* by *WADA*.

When an *Anti-Doping Organization* fails to take action on a properly submitted therapeutic use exemption application within a reasonable time, the *Anti-Doping Organization's* failure to decide may be considered a denial for purposes of the appeal rights provided in this Article.

Code Article 14.5 Doping Control Information Clearinghouse

WADA shall act as a central clearinghouse for *Doping Control Testing* data and results for *International-Level Athletes* and national-level *Athletes* who have been included in their *National Anti-Doping Organization's Registered Testing Pool*. To facilitate coordinated test distribution planning and to avoid unnecessary duplication in *Testing* by the various *Anti-Doping Organizations*, each *Anti-Doping Organization* shall report all *In-Competition* and *Out-of-Competition* tests on such *Athletes* to the *WADA* clearinghouse as soon as possible after such tests have been conducted. This information will be made accessible to the *Athlete*, the *Athlete's National Federation*, *National Olympic Committee* or *National Paralympic Committee*, *National Anti-Doping Organization*, *International Federation*, and the *International Olympic Committee* or *International Paralympic Committee*.

To enable it to serve as a clearinghouse for *Doping Control Testing* data, *WADA* has developed a database management tool, *ADAMS*, that reflects emerging data privacy principles. In particular, *WADA* has developed *ADAMS* to be consistent with data privacy statutes and norms applicable to *WADA* and other organizations using *ADAMS*.

, (2.1), (2.2), (2.6), (2.8) , .

13.4 가

가 , 가 13.2.2 가

가

14.5

가

가 가 , 가 가 , 가 가

가

(ADAMS)

Private information regarding an *Athlete, Athlete Support Personnel*, or others involved in anti-doping activities shall be maintained by *WADA*, International which is supervised by Canadian privacy authorities, in strict confidence and in accordance with the *International Standard* for the protection of privacy. *WADA* shall, at least annually, publish statistical reports summarizing the information that it receives, ensuring at all times that the privacy of *Athletes* is fully respected and make itself available for discussions with national and regional data privacy authorities.

Code Article 15.4 Mutual Recognition

15.4.1 Subject to the right to appeal provided in Article 13, *Testing*, therapeutic use exemptions and hearing results or other final adjudications of any *Signatory* which are consistent with the *Code* and are within that *Signatory's* authority, shall be recognized and respected by all other *Signatories*.

[Comment to Article 15.4.1: There has in the past been some confusion in the interpretation of this Article with regard to therapeutic use exemptions. Unless provided otherwise by the rules of an International Federation or an agreement with an International Federation, National Anti-Doping Organizations do not have "authority" to grant therapeutic use exemptions to International-Level Athletes.]

15.4.2 *Signatories* shall recognize the same actions of other bodies which have not accepted the *Code* if the rules of those bodies are otherwise consistent with the *Code*.

[Comment to Article 15.4.2: Where the decision of a body that has not accepted the Code is in some respects Code compliant and in other respects not Code compliant, Signatories should attempt to apply the decision in harmony with the principles of the Code. For example, if in a process consistent with the Code a non-Signatory has found an Athlete to have committed an anti-doping rule violation on account of the presence of a Prohibited Substance in his body but the period of Ineligibility applied is shorter than the period provided for in the Code, then all Signatories should recognize the finding of an anti-doping rule violation and the Athlete's National Anti-Doping Organization should conduct a hearing consistent with Article 8 to determine whether the longer period of Ineligibility provided in the Code should be imposed.]

3.0 Terms and Definitions

3.1 Defined Terms from the Code

ADAMS: The Anti-Doping Administration and Management System is a Webbased database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and *WADA* in their anti-doping operations in conjunction with data protection legislation.

가
가
15.4
15.4.1 13
가
[15.4.1 :
가
15.4.2 가
[15.4.2 :
가
가
가
가
8
.]

3.0 용어의 정의

3.1

(ADAMS):

Code: The World Anti-Doping Code.

Competition: A single race, match, game or singular athletic contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other athletic contests where prizes are awarded on a daily or other interim basis the distinction between a *Competition* and an *Event* will be as provided in the rules of the applicable International Federation.

Doping Control: All steps and processes from test distribution planning through to ultimate disposition of any appeal including all steps and processes in between such as provision of whereabouts information, *Sample* collection and handling, laboratory analysis, therapeutic use exemptions, results management and hearings.

Event: A series of individual *Competitions* conducted together under one ruling body (e.g., the Olympic Games, FINA World Championships, or Pan American Games).

Event Period: The time between the beginning and end of an *Event*, as established by the ruling body of the *Event*.

In-Competition: Unless provided otherwise in the rules of an International Federation or other relevant *Anti-Doping Organization*, "*In-Competition*" means the period commencing twelve hours before a *Competition* in which the *Athlete* is scheduled to participate through the end of such *Competition* and the *Sample* collection process related to such *Competition*.

International Event: An *Event* where the International Olympic Committee, the International Paralympic Committee, an International Federation, a *Major Event Organization*, or another international sport organization is the ruling body for the *Event* or appoints the technical officials for the *Event*.

International-Level Athlete: *Athletes* designated by one or more International Federations as being within the *Registered Testing Pool* for an International Federation.

International Standard: A standard adopted by WADA in support of the *Code*. Compliance with an *International Standard* (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the *International Standard* were performed properly. *International Standards* shall include any Technical Documents issued pursuant to the *International Standard*.

(Code): "The World Anti-Doping Code"

100

가

가 가 가 12

가

(가)

3.2 Defined Terms from the International Standard for TUEs

Retroactive TUE: Therapeutic use exemption approved by a Therapeutic Use Exemption Committee based on a documented medical file after a laboratory has reported an *Adverse Analytical Finding (AAF)*.

Therapeutic: Of or relating to the treatment of a medical condition by remedial agents or methods; or providing or assisting in a cure.

TUE: Therapeutic use exemption approved by a Therapeutic Use Exemption Committee based on a documented medical file before the *Use* of the substance in sports.

TUEC: Therapeutic Use Exemption Committee is the Panel established by the relevant *Anti-Doping Organization*.

WADA TUEC: WADA Therapeutic Use Exemption Committee is the Panel established by WADA.

3.2

_____ (Retroactive TUE) :

_____ :

_____ (TUE) :

_____ (TUEC) :

_____ (WADA TUEC) :
(WADA)가

PART TWO: STANDARDS FOR GRANTING THERAPEUTIC USE EXEMPTIONS

4.0 Criteria for Granting a Therapeutic Use Exemption

A therapeutic use exemption (TUE) may be granted to an *Athlete* permitting the Use of a *Prohibited Substance* or *Prohibited Method* contained in the *Prohibited List*. An application for a TUE will be reviewed by a *Therapeutic Use Exemption Committee (TUEC)*. The TUEC will be appointed by an *Anti-Doping Organization*. An exemption will be granted only in strict accordance with the following criteria:

[Comment: This Standard can apply to all Athletes as defined by and subject to the Code, i.e. able-bodied Athletes and Athletes with disabilities. This Standard will be applied according to an individual's circumstances. For example, an exemption that is appropriate for an Athlete with a disability may be inappropriate for other Athletes.]

4.1 The *Athlete* should submit an application for a TUE no less than twenty-one (21) days before he/she needs the approval (for instance an *Event*).

4.2 The *Athlete* would experience a significant impairment to health if the *Prohibited Substance* or *Prohibited Method* were to be withheld in the course of treating an acute or chronic medical condition.

4.3 The *therapeutic Use* of the *Prohibited Substance* or *Prohibited Method* would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. The Use of any *Prohibited Substance* or *Prohibited Method* to increase "low-normal" levels of any endogenous hormone is not considered an acceptable *therapeutic* intervention.

4.4 There is no reasonable *therapeutic* alternative to the Use of the otherwise *Prohibited Substance* or *Prohibited Method*.

4.5 The necessity for the Use of the otherwise *Prohibited Substance* or *Prohibited Method* cannot be a consequence, wholly or in part, of prior non-*therapeutic* Use of any substance from the *Prohibited List*.

4.6 The TUE will be cancelled by the granting body, if:

- a. The *Athlete* does not promptly comply with any requirements or conditions imposed by the *Anti-Doping Organization* granting the exemption.
- b. The term for which the TUE was granted has expired.

제2장 : 치료목적사용면책 승인 기준

4.0 치료목적사용면책 승인 기준

(TUEC)가 가

[주해: 이 기준은 세계반도핑규약에 정의된 모든 선수 즉, 건강한 선수와 장애인선수에게 적용된다. 이 기준은 개별 선수의 상황에 따라 적용된다. 예를 들어, 장애인선수에게 적절한 면책이 다른 선수에게는 부적절할 수 있다.]

4.1 (,) 21

4.2 , 가

4.3 가 가

4.4 가

4.5

4.6

a. 가 가

b.

c. The Athlete is advised that the TUE has been withdrawn by the Anti-Doping Organization.

[Comment: Each TUE will have a specified duration as decided upon by the TUEC. There may be cases when a TUE has expired or has been withdrawn and the Prohibited Substance subject to the TUE is still present in the Athlete's body. In such cases, the Anti-Doping Organization conducting the initial review of an adverse analytical finding will consider whether the finding is consistent with expiry or withdrawal of the TUE.]

4.7 An application for a TUE will not be considered for retroactive approval except in cases where:

- a. Emergency treatment or treatment of an acute medical condition was necessary, or
- b. due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to consider, an application prior to Doping Control, or
- c. the conditions set forth under 7.13 apply.

[Comment: Medical emergencies or acute medical situations requiring administration of an otherwise Prohibited Substance or Prohibited Method before an application for a TUE can be made, are uncommon. Similarly, circumstances requiring expedited consideration of an application for a TUE due to imminent competition are infrequent. Anti-Doping Organizations granting TUEs should have internal procedures which permit such situations to be addressed.]

5.0. Confidentiality of Information

5.1 The applicant must provide written consent for the transmission of all information pertaining to the application to members of the TUEC and, as required, other independent medical or scientific experts, or to all necessary staff involved in the management, review or appeal of TUEs.

Should the assistance of external, independent experts be required, all details of the application will be circulated without identifying the Athlete concerned. The applicant must also provide written consent for the decisions of the TUEC to be distributed to other relevant Anti-Doping Organizations under the provisions of the Code.

5.2 The members of the TUECs and the administration of the Anti-Doping Organization involved will conduct all of their activities in strict confidence. All members of a TUEC and all staff involved will sign confidentiality agreements. In particular they will keep the following information confidential:

c.
[: 가
가 ,
가
.]

4.7

- a. 가 ,
- b. 가 ,
- c. 7.13

[: 가 ,
가 ,
가 .]

5.0 개인정보 보호

5.1 , 가, 가 , 가

가 ,

5.2

- a. All medical information and data provided by the *Athlete* and physician(s) involved in the *Athlete's* care.
- b. All details of the application including the name of the physician(s) involved in the process.

Should the *Athlete* wish to revoke the right of the TUEC or the WADA TUEC to obtain any health information on his/her behalf, the *Athlete* must notify his/her medical practitioner in writing of the fact. As a consequence of such a decision, the *Athlete* will not receive approval for a TUE or renewal of an existing TUE.

6.0 Therapeutic Use Exemption Committees (TUECs)

TUECs shall be constituted and act in accordance with the following guidelines:

6.1 TUECs should include at least three (3) physicians with experience in the care and treatment of *Athletes* and a sound knowledge of clinical, sports and exercise medicine. In order to ensure a level of independence of decisions, the majority of the members of any TUEC should be free of conflicts of interest or political responsibility in the *Anti-Doping Organization*. All members of a TUEC will sign a conflict of interest agreement. In applications involving *Athletes* with disabilities, at least one TUEC member must possess specific experience with the care and treatment of *Athletes* with disabilities.

6.2 TUECs may seek whatever medical or scientific expertise they deem appropriate in reviewing the circumstances of any application for a TUE.

6.3 The WADA TUEC shall be composed following the criteria set out in Article 6.1. The WADA TUEC is established to review on its own initiative TUE decisions granted by *Anti-Doping Organizations*. As specified in Article 4.4 of the *Code*, the WADA TUEC, upon request by *Athletes* who have been denied TUEs by an *Anti-Doping Organization*, will review such decisions with the power to reverse them.

7.0 Therapeutic Use Exemption (TUE) Application Process

7.1 A TUE will only be considered following the receipt of a completed application form that must include all relevant documents (see Annex 2 - TUE form). The application process must be dealt with in accordance with the principles of strict medical confidentiality.

- a. 가
- b. .

가

6.0 치료목적사용면책위원회 (TUECs)

6.1

3

가

가

1

6.2

가

6.3

6.1

가

4.4

7.0 치료목적사용면책(TUE) 신청 절차

7.1

.(2)

가

7.2 The TUE application form(s), as set out in Annex 2, can be modified by *Anti-Doping Organizations* to include additional requests for information, but no sections or items shall be removed.

7.3 The TUE application form(s) may be translated into other language(s) by *Anti-Doping Organizations*, but English or French must remain on the application form(s).

7.4 An *Athlete* may not apply to more than one *Anti-Doping Organization* for a TUE. The application must identify the *Athlete's* sport and, where appropriate, discipline and specific position or role.

7.5 The application must list any previous and/or current requests for permission to use an otherwise *Prohibited Substance* or *Prohibited Method*, the body to whom that request was made, and the decision of that body.

7.6 The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. The arguments related to the diagnosis and treatment, as well as duration of validity, should follow the *WADA "Medical Information to Support the Decisions of TUECs"*. For asthma, the specific requirement(s) set out in Annex 1 must be fulfilled.

7.7 Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the *Anti-Doping Organization* before approval will be undertaken at the expense of the applicant or his/her national sport governing body.

7.8 The application must include a statement by an appropriately qualified physician attesting to the necessity of the otherwise *Prohibited Substance* or *Prohibited Method* in the treatment of the *Athlete* and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.

7.9 The dose, frequency, route and duration of administration of the otherwise *Prohibited Substance* or *Prohibited Method* in question must be specified. In case of change, a new application should be submitted.

7.10 In normal circumstances, decisions of the TUEC should be completed within thirty (30) days of receipt of all relevant documentation and will be conveyed in writing to the *Athlete* by the relevant *Anti-Doping Organization*. In case of a TUE application made in a reasonable time limit prior to an *Event* the TUEC should use its best endeavors to complete the TUE process before the start of the *Event*. Where a TUE has been granted to an *Athlete* in the *Anti-Doping Organization Registered Testing Pool*, the *Athlete* and *WADA* will be provided promptly with an approval which includes information pertaining to the duration of the exemption and any conditions associated with the TUE.

7.2 2 가 가

7.3 가

7.4 1

7.5 가

7.6 “ ” 1

7.7 가 가 가

7.8 가 가

7.9

7.10 30 가

7.11 a. Upon receiving a request by an *Athlete* for review, the WADA TUEC will, as specified in Article 4.4 of the *Code*, be able to reverse a decision on a TUE denied by an *Anti-Doping Organization*. The *Athlete* shall provide to the WADA TUEC all the information for a TUE as submitted initially to the *Anti-Doping Organization* accompanied by an application fee. Until the review process has been completed, the original decision remains in effect. The process should not take longer than thirty (30) days following receipt of all the information by *WADA*.

b. *WADA* can, on its own initiative, undertake a review at any time.

7.12 If the decision regarding the granting of a TUE is reversed by *WADA* upon review, the reversal shall not apply retroactively and shall not disqualify the *Athlete's* results during the period that the TUE had been granted and shall take effect no later than fourteen (14) days following notification of the decision to the *Athlete*.

7.13 The *Use* of inhaled Beta-2 Agonists:

- The *Use* of inhaled formoterol, salbutamol, salmeterol, terbutaline reflects current clinical practice. The *Use* of these substances should be declared on *ADAMS* where reasonably feasible and in accordance with the *Code* as soon as the product is used and must as well be declared on the *Doping Control* form at the time of *Testing*. Failure to declare will be taken into account in the result management process in particular in case of application for a Retroactive TUE.
- *Athletes* using the substances listed above by inhalation must have a medical file justifying this *Use* and meeting the minimum requirements outlined in Annex 1.

Depending upon the category of the *Athlete*, the medical file will be evaluated as follows:

- For all *Athletes* included in an International Federation *Registered Testing Pool* a regular TUE approved before the *Use* of the substance.
- For *Athletes* participating in an *International Event* but who are not included in an *International Federation Registered Testing Pool* either a TUE, or a Retroactive TUE in the case of an *Adverse Analytical Finding*, in accordance with the rule of the International Federation or of the *Major Event Organization*.
- For national-level *Athletes* who are not included in an *International Federation Registered Testing Pool*, whether or not they are part of a national *Registered Testing Pool*, either a TUE, or a Retroactive TUE in the case of an *Adverse Analytical Finding*, in accordance with the rules of the *National Anti-Doping Organization*.

7.11 a. 4.4 가 30

b. 7.12 가 14

7.13 Beta-2
 - formoterol, salbutamol, salmeterol, terbutaline 가
 (ADAMS)
 - 1
 가
 가

10.0 Transitional provision

Abbreviated Therapeutic Use Exemptions (ATUEs) delivered prior to December 31, 2008 shall remain governed by the 2005 TUE Standard.

These ATUEs shall remain valid after January 1, 2009 until the earliest of:

- (i) The date on which they are cancelled by the competent TUEC following review in accordance with art. 8.6 of the 2005 TUE Standard ;
- (ii) Their expiry date as mentioned on the ATUE ;
- (iii) December 31, 2009.

10.0 경과규정

2008 12 31 2005

2009 1 1

(i) 2005 8.6
가

(ii)

(iii) 2009 12 31

ANNEX 1:

Minimal requirements for the medical file to be used for the TUE process in the case of asthma and its clinical variants

The file must reflect current best medical practice to include:

- 1) A complete medical history
- 2) A comprehensive report of the clinical examination with specific focus on the respiratory system
- 3) A report of spirometry with the measure of the Forced Expiratory Volume in 1 second (FEV1)
- 4) If airway obstruction is present, the spirometry will be repeated after inhalation of a short acting Beta-2 Agonist to demonstrate the reversibility of bronchoconstriction
- 5) In the absence of reversible airway obstruction, a bronchial provocation test is required to establish the presence of airway hyper-responsiveness
- 6) Exact name, speciality, address (including telephone, e-mail, fax) of examining physician.

부 록 1:

천식 및 그의 임상적 변형의 경우 치료목적사용면책 절차를 위하여 필요한 최소한의 의료적 증빙 자료 요구조건

- 1)
- 2)
- 3) 1 (FEV1)
- 4) 가 (可逆性) 2- 1 (FEV1)
- 5) 가
- 6) , , (, e-mail,)

ANNEX 2:

Therapeutic use exemption application form

Identification of Anti-Doping Organization
(Logo or Name of the ADO)

Application form

Therapeutic Use Exemptions TUE

Please complete all sections in capital letters or typing

1. Athlete Information

Surname: Given Names:

Female Male Date of Birth(d/m/y):

Address:

City: Country: Postcode:

Tel. (with international code): E-mail:

Sport: Discipline/Position:

International or National Sport Organization:

If athlete with disability, indicate disability:

2. Medical information

Diagnosis with sufficient medical information (see note 1):
.....
.....
.....

If a permitted medication can be used to treat the medical condition, provide clinical justification for the requested use of the prohibited medication
.....
.....
.....

3. Medication details

Prohibited substance(s): Generic name	Dose	Route	Frequency
1.			
2.			
3.			
Intended duration of treatment: (Please tick appropriate box)	once only <input type="checkbox"/> emergency <input type="checkbox"/> or duration (week/month):		

Have you submitted any previous TUE application: yes no

For which substance?.....

To whom?.....When?.....

Decision: Approved Not approved

4. Medical practitioner's declaration

I certify that the above-mentioned treatment is medically appropriate and that the use of alternative medication not on the prohibited list would be satisfactory for this condition.

Name:.....

Medical specialty:

Address:

Tel.:

Fax:

E-mail:

Signature of Medical Practitioner:Date:

5. Athlete's declaration

I,certify that the information under 1. is accurate and that I am requesting approval to use a Substance or Method from the WADA Prohibited List. I authorize the release of personal medical information to the Anti-Doping Organization (ADO) as well as to WADA staff, to the WADA TUEC (Therapeutic Use Exemption Committee) and to other ADO under the provisions of the Code. I understand that if I ever wish to revoke the right of these organizations to obtain my health information on my behalf, I must notify my medical practitioner and my ADO in writing of that fact.

Athlete's signature: **Date:**

Parent's/Guardian's signature: **Date:**

(if the athlete is a minor or has a disability preventing him/her to sign this form, a parent or guardian shall sign together with or on behalf of the athlete)

6. Note:

Note 1 Diagnosis

Evidence confirming the diagnosis must be attached and forwarded with this application. The medical evidence should include a comprehensive medical history and the results of all relevant examinations, laboratory investigations and imaging studies. Copies of the original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances and in the case of non-demonstrable conditions independent supporting medical opinion will assist this application.

Incomplete Applications will be returned and will need to be resubmitted.

Please submit the completed form to the ADO and keep a copy for your records.

부 록 2:

부 록 2:



**치료목적사용 면책신청서
Therapeutic Use Examination (TUE)**

/Please complete all sections in capital letters or typing.

1. 선수 인적사항/Athlete Information

/Surname:..... /Given Name:.....
 /Female /Male /Date of Birth(y/m/d):.....
 /Address:.....(/Postcode).....
 /Tel.:..... /E-mail :.....
 Sport :..... Discipline/Position :..... National Sports Federation :.....
 () :.....
 If athlete with disability, indicate disability

2. 의료정보/Medical Information

/Diagnosis with sufficient medical information:.....

 가 가 ,
 /If a permitted medication can be used to treat the medical condition, provide clinical justification for the requested use of the prohibited medication:.....

* 가 . 가
 가
 /Evidence confirming the diagnosis must be attached and forwarded with this application. The medical evidence should include a comprehensive medical history and the results of all relevant examinations, laboratory investigations and imaging studies. Copies of the original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances and in the case of non-demonstrable conditions independent supporting medical opinion will assist this application.

3. 세부 진료내용/Medication details

/Prohibited substance(s): /Generic name	1	/Dose	/Route	/Frequency
1.				
2.				
3.				

/Intended duration of treatment: 1 /once only /emergency
 기간(주/월)/duration (week/month).....
 TUE /Have you submitted any previous TUE application:
 /yes /no
 /For which substance.....
 /To Whom..... /When.....
 /Decision /Approved /Not approved

4. 담당의사 선서/Medical practitioner's declaration

....., /I certify that the above-mentioned treatment is medically appropriate and that the use of alternative medication not on the prohibited list would be unsatisfactory for this condition.
 /Name:.....
 /Medical speciality:.....
 /Address:.....
 /Tel.:..... /Fax:..... /E-mail:.....
 /Signature of Medical Practitioner:..... /Date:.....

5. 선수 선서/Athlete's declaration

..... ()
 (WADA) 가 가 (TUEC) , WADA , WADA 가 가
 /I,certify that the information under 1. is accurate and that I am requesting approval to use a Substance or Method from the WADA Prohibited List. I authorize the release of personal medical information to the Korea Anti-Doping Agency (KADA) as well as to WADA staff, to the WADA TUEC (Therapeutic Use Exemption Committee) and to other ADO under the provisions of the Code. I understand that if I ever wish to revoke the right of these organizations to obtain my health information on my behalf, I must notify my medical practitioner and my ADO in writing of that fact.
 /Athlete's Signature:..... /Date:.....
 / Parent's Signature:..... /Date:.....
 (가 가 가 가
 /If the athlete is a minor or has a disability preventing him/her to sign this form, a parent or guardian shall sign together with or on behalf of the athlete)

6. 소속 경기단체의 확인/Confirmation of National Sports Federation

Chief Medical Officer been notified of this request? /Has the National Sports Federation
 /yes /no
 소속 경기단체 의무분과위원장/Name of NSF's Chief Medical Officer
 성명/Name:..... 서명/Signature:.....

..... /Incomplete Applications will be returned and will need to be resubmitted. Please submit the completed form to the ADO and keep a copy for your records.

KADA 결정/KADA decision (KADA 가)

/ Application No.:	/Application complete: /yes <input type="checkbox"/> /no <input type="checkbox"/>	/Decision /Approved <input type="checkbox"/> /Not Approved <input type="checkbox"/>
--------------------	--	--

KADA 연락처/KADA contact details

주소: 서울 송파구 방이2동 66-2 세기빌딩 802호
 전화: 02-421-1622 팩스: 02-419-0220 이메일: admin@kada-ad.or.kr

Please submit the completed form to the KADA and keep a copy for your records.

부 록 3:



치료목적사용면책위원회 판정서
TUE Committee Decision

Please complete all sections in capital letters or typing.

치료목적사용면책위원회 구성/Constitution of TUE Committee

위원장/Chairman :

위원/Member:

위원/Member:

위원/Member:

위원/Member:

선수 정보/Athlete's information :

성명/Name:

서류번호/File number:

사용약물/Substance:

치료목적사용면책위원회 판정/TUEC Decision :

승인/Grant 거부/Refusal

거부 시 거부사유/In case of refusal, reasons:

.....

.....

판정일/Date of decision:시효만료일/Date of expiration.....